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Abstract
Background: Social Anxiety Disorder (SAD) is a common disorder and its high prevalence and
lifelong chronicity are such that it represents a substantial public health problem. The observation
that serotonergic agents appear to be effective for its treatment suggests that patients may have
abnormal serotonergic neurotransmission within the central nervous system. We investigated the
efficacy of Escitalopram in treatment resistant patients with SAD.
Method: Twenty-nine adult outpatients participated in a 12-week open-label trial of escitalopram.
All the subjects had a primary diagnosis of SAD and had failed at least one previous adequate trial
of paroxetine. Escitalopram was orally administered starting with a dose of 10 mg/day following a
1-week titration.
Results: The escitalopram treatment was characterized by good tolerability (drop-out rate due to
intolerance: 10.3%), and 24 subjects completed the study trial. At the end of the 12-week treatment
period, 14 subjects (48.3%) were considered as responders on the basis of the Clinical Global
Impression-Improvement (CGI-I) (much or very much improved) scale and the Liebowitz Scale for
Social Anxiety (LSAS) (reduction >35% compared to baseline).
We observed a significant mean reduction in the Sheehan Disability Scale Work (p < .05) and Social
(p < .05) subscores, but not in the Family subscore.
Conclusion: These data suggest escitalopram has a role in the treatment of resistant SAD,
especially in view of the favourable tolerability profile observed in the patients. Controlled studies
are required to further investigate these findings and to compare escitalopram with other
treatments for this disorder.
Background
Selective serotonin reuptake inhibitors (SSRIs) are being
used more frequently as treatment for generalized and
specific Social Anxiety Disorder (SAD), a common illness
with significant associated disability. Estimates of lifetime
prevalence in adult samples, when modern diagnostic cri-
teria are used, range from 3.9% to 13.7% [1,2]. The prev-
alence estimates are generally higher in women than in
men.
Individuals with SAD are more likely to develop disabili-
ties in the areas of school, work, and social life, with par-
ticular problems initiating relationships with the opposite
sex. Furthermore, increased disability and a reduced qual-
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ity of life, as well as increasing rates of comorbidity with
secondary mental disorders (e.g., depression, substance
abuse) can be expected to develop over time [3].
The stability of the SSRI effect size estimate in conjunction
with other evidence for safety and tolerability, and the
ability of SSRIs to treat comorbid conditions, support
their use as a first-line treatment [4,5].
More specifically, paroxetine was the first SSRI indicated
for the treatment of SAD, and its efficacy in the treatment
of acute social anxiety disorder has been clearly demon-
strated in four 12-week, randomized, placebo-controlled
studies [6-9]. More recently, paroxetine's effectiveness in
the long-term treatment of SAD has also been shown [10].
However, about 50% of cases do not respond to a first
SSRI treatment. Treatment resistance has been a topic of
interest in many psychiatric disorders, but clear and stand-
ardized definitions of response, resistance and remission
to treatment in SAD warrant further discussion and need
to be based on empirical data [11].
The results of several studies suggest that citalopram may
be a safe and effective treatment for SAD, including
patients who have failed to tolerate or respond to a prior
treatment trial [12-14]. A recent investigation showed that
patients with SAD and healthy controls did not display
differences to a citalopram challenge (20 mg over 30 min)
in terms of 5-HT neuroendocrine response measured as
increased plasma concentrations of prolactin and cortisol
[15]. However the finding of an increased headache
response in patients with SAD may indicate hypersensitiv-
ity of the serotonergic pathways related to some subtypes
of 5-HT2  or 5-HT3  receptors following the citalopram
administration [15].
Headache is a well-known side effect of serotonergic med-
ications. The specific mechanism responsible for SSRI-
induced headache is not clear and it is usually attributed
to the agonistic effects on the post-synaptic 5-HT recep-
tors. Citalopram is a racemic drug, and its effects on sero-
tonin transport are thought to reside in the S-enantiomer,
known as (S)-citalopram or escitalopram. Escitalopram is
the most selective SSRI yet developed. Its receptor binding
properties and activity in preclinical animal models of
depression predict the effectiveness of escitalopram in the
treatment of depression, with approximately twice the
potency of the racemate [16,17].
Escitalopram has shown significant superiority to placebo
in controlled clinical trials of depression, social anxiety
disorder, generalized anxiety disorder, and anxiety symp-
toms associated with major depression [18-24]. In
December 2003 escitalopram received FDA approval for
the treatment of Generalized Anxiety Disorder.
The aim of the present study is to investigate the effective-
ness and tolerability of escitalopram in a group of treat-
ment-resistant patients with SAD.
Methods
A. Subjects
Twenty-nine adult outpatients at the Institute for Neuro-
sciences in Florence (Italy) were consecutively enrolled in
the study from January to June 2006. All the subjects met
the DSM-IV criteria for the diagnosis of SAD, present for
at last one year, and established by means of the struc-
tured clinical interview for DSM-IV (SCID-I, SCID-II). The
SCID interviews were conducted by two psychiatrists (LQ,
ARP) certified for the use of this instrument.
All the patients had previously failed at least one adequate
trial of paroxetine treatment(>= 60 mg/d for >= 12
weeks). Paroxetine was the only labeled approved drug for
SAD in Italy. Recently, also escitalopram has been
approved in Italy for SAD treatment. "Failure" was
defined as: 1. experiencing less than a 35% decrease from
baseline in the Liebowitz Scale for Social Anxiety total
score, and a score of 'minimal improvement' or less on the
Clinical Global Improvement scale (CGI) after 12 weeks
of treatment. The mean length of these failed trials was
18.1 weeks, sd 4.2, during which each patient had been
pushed to the maximum tolerated medication dose; 2.
having stopped the medication in the first 3 weeks of
treatment because of intolerable side effects or lack of
compliance.
Patients with a concurrent diagnosis of major depressive
episode or marked depressive symptoms scoring >18 on
the 21-item Hamilton Depression Rating Scale (HDRS)
were excluded from the study. Other exclusion criteria
were: a concurrent Axis-I diagnosis (DSM-IV) for schizo-
phrenia or other psychotic syndromes; any form of sub-
stance dependence (active in the last year) or any
substance abuse including alcohol within the last three
months; Tourette syndrome or other tic disorders, Bipo-
lar-I disorder, organic brain syndromes, pregnancy, nurs-
ing, active suicidal thoughts or serious suicide risk. Ten of
the 29 subjects (34.5%) reported having failed to respond
satisfactorily to an adequate period (at least 16 consecu-
tive appointments) of cognitive psychotherapy. No cogni-
tive or behavioral psychotherapy was allowed during the
treatment and follow-up period.
After receiving an explanation of the potential risks and
benefits of the escitalopram treatment and of alternative
treatments, each patient gave written informed consent in
accordance with the Declaration of Helsinki.Clinical Practice and Epidemiology in Mental Health 2006, 2:35 http://www.cpementalhealth.com/content/2/1/35
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B. Protocol
The study was a 12-week open trial of escitalopram treat-
ment. After this period, patients who showed at least
moderate response to treatment (>= 35% reduction of
LSAS total score) continued open treatment with escitalo-
pram at the maximal received dose until day 84. Patients
who showed no change after the 12-week period were
offered a co-treatment with a different SSRI, or MAOI was
started.
The escitalopram treatment began after a 1-week (two
weeks for fluoxetine) washout period. The escitalopram
titration dosing was established as follows: 10 mg during
days 1 to 7, 20 mg from day 8. It was established that the
minimum tolerated citalopram dose for persisting in the
study was 10 mg. Tablets were to be taken once a day in
the morning. During the study period, the only permitted
co-treatment for controlling sleep disorders was a low-
dose benzodiazepine medication (lorazepam 1–2 mg,
temazepam 20 mg daily).
C Assessment
At baseline, all the patients were assessed with the SCID-I
and SCID-II diagnostic interviews, the Liebowitz Scale for
Social Anxiety (LSAS), the CGI-I and CGI-S (Clinical Glo-
bal impression scales for -Improvement and -Severity),
the Sheean Disability Scale (SDS), the Arizona Sexual
Experience Scale (ASEX), and the Hamilton Depression
Rating Scale (HDRS). The LSAS, the CGI-I and CGI-S, and
the Dosage Record and Treatment Emergent Symptom
Scale (DOTES) for side effects were administered at each
assessment visit pre-planned at days 14-28-42-56-70-84.
At day 28–56 and 84 the ASEX and the SDS were repeated.
The LSAS and CGI-S were used as the primary efficacy var-
iable. ASEX and SDS scales were considered as secondary
efficacy indicators.
D Statistical analysis
Mean values and SD and ranges were calculated for all
parametric variables. Interrater reliability was ascertained
through a series of live independent ratings by the authors
(S.P., L.Q.) and yielded intraclass correlations of 0.88 for
the HDRS (Cronbach α). Student t-tests for independent
variables, ANOVA for repeated measures, Pearson-rho
correlation coefficients were performed where appropri-
ate, with alpha set at p < 0.05, two tailed. Data were ana-
lyzed using an SPSS-PC package, running on a Pentium-II
PC compatible.
Results
The demographic and clinical characteristics of the sub-
jects are presented in Table 1. Of the 29 patients enrolled
for the trial, 24 (82.7%) completed the 3-month period of
treatment with Escitalopram. Three patients dropped out
of the trial due to non-compliance without significant
side effects, and two patients interrupted the trial in the
first week of treatment for adverse effects, in particular
increased anxiety/agitation. Other relatively common
treatment-emergent side effects observed during the trial
were nausea (20.7% cases), anxiety (17.2%), headache
(17.2%), somnolence (10.3%), fatigue (6.9%) and
diarrhea (6.9%).
At the end of the 12-week period of treatment, 2 patients
were receiving escitalopram 10 mg/day, 3 patients 15 mg/
day and 19 patients 20 mg/day. The mean maximum esci-
talopram dose received by subjects who completed the
12-week trial was 18.54 mg (sd: 3.12). The mean daily
escitalopram dose received by each subject across the 12-
week period was 16.22 mg (sd: 4.21).
Compared to baseline, the mean LSAS total score dropped
over the 12 weeks of treatment to 33.21 sd 6.12 (n = 29)
(ANOVA-F repeated meas. = 9.62, df:1,28; p < .01) (see
figure 1). The range of LSAS scores fell from 51–80 to 12–
61. The mean reduction in total LSAS scores was -23.2 sd
8.3 (range +6/-52), which represented a percentage reduc-
tion of -37.18% sd 12.9 (range +12.7%/-66.6%). Of the
subjects who completed the trial period, 14 (48.3%)
patients experienced an LSAS total score decrease of >=
35%, 5 of them (17.2%) an LSAS score decrease of >=
50%. Depressive symptoms, expressed as a mean HSRD
score, were not considered as an efficacy measure in the
present study. However, they appeared to have reduced
significantly after 3 weeks (end of the trial: m = 8.11,
sd:3.05; ANOVA-F repeated meas.: 7.28, df:1.28 p < .03).
The amelioration of the social phobia symptoms was
reflected also by a mean reduction of CGI-S scores, which
reached significance from the 6th week of treatment (base-
line: m: 4.8, sd: 1.1; end of trial: m: 2.2, sd:1.3, ANOVA-F
repeated meas.: 9.37, df: 1.28, p < .01).
The maximal daily escitalopram dose showed a positive
but not significant correlation with the reduction of the
LSAS total score after 12 weeks (Pearson-ρ :.32, n = 29,
n.s.). At the end of the trial we observed a significant
reduction in the Sheehan Disability Scale Work (m: 5.3,
sd: 1.7; ANOVA-F repeated meas.: 6.11, df: 1,28, p < .05)
and Social subscores (m: 6.4, sd: 1.9; ANOVA-F repeated
meas.: 6.81, df: 1,28, p < .05), but not in the Family sub-
score (m: 4.6, sd: 1.3; ANOVA-F repeated meas.: 3.19, df:
1,28, n.s), compared to the baseline.
After 12 weeks of treatment, social phobic patients
showed a reduction of severity and pervasiveness of sexual
side effects as reported through the ASEX scale. In particu-
lar, significant amelioration was found on the Erection/
Lubrication (F = 6.74, df = 1,28; p < .05), Orgasm (F =
5.81, df = 1,28, p < .05), and Satisfaction (F = 6.55, p <
.05) subscales (all df = 1, 28). No significant differencesClinical Practice and Epidemiology in Mental Health 2006, 2:35 http://www.cpementalhealth.com/content/2/1/35
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were found in the Libido and Arousal subscales (see figure
2)
Discussion
The main result of the study is the significant mean reduc-
tion of LSAS scores and CGI-S scores (primary indicators)
in resistant social phobic patients after a 12-week period
of escitalopram treatment. A progressive reduction of
LSAS scores was rated and reached significance from the
6th week of treatment. The SDS scales indicated that clini-
cal improvement corresponded to a significant reduction
of social disability related to the disorder, at least in the
work and social spheres. The LSAS Anxiety subscore
decreased earlier and more significantly than the Avoid-
ance subscore through to the 6th week of treatment. This is
in accordance with the observation that behavioral amel-
ioration of SAD in response to treatment follows the
reduction of psychological anxiety states related to social
contexts. However, we were unable to ascertain whether
subjects with resistant SAD are a homogeneous subsam-
ple amongst SAD patients. The main limit of the present
study is its open-label design and the lack of a placebo
group, so it is hard to say how much the placebo effect is
responsible for the positive results. Nor does it account for
experimenter bias. In fact, one of the limits of this study is
that it did not consider the weight of single comorbidities,
especially in resistant subjects, and their possible impact
on the response to treatment. Furthermore, it cannot be
excluded that other classes of drugs (e.g., anticonvulsants)
might be useful in some resistant SAD subjects depending
on the impact of the comorbid condition (e.g., bipolar
spectrum disorders) on SAD. About 50% of the initially
enrolled subjects were classified as responders to escitalo-
pram. This percentage is consistent, taking into account
that all the subjects were previously resistant to paroxetine
treatment. While the effectiveness of escitalopram in SAD
has already been reported, this is the first study of escita-
lopram treatment in subjects with resistant SAD [20]. The
drop-out rate in the 3-month trial period was 17.3%, sug-
gesting an average good tolerability and mild side effects
profile for escitalopram in this group of subjects. The
drop-out rate resembles that found by Lader et al, while it
appears higher than that found by Kasper et al among
patients with SAD treated with escitalopram [20,21].
Table 1: Demographic and clinical characteristics of the group of 29 patients with resistant Social Anxiety Disorder (SAD) enrolled in 
the study.
Age m: 34.6 sd: 9.9 (range 24–42)
Gender 13 M (44.8%)/16 F (55.2%)
Education level (yrs) m: 12.3 sd: 4.6
Marital status Single n = 9 (31%)
Married n = 16 (55.2%)
Divorced n = 4 (13.8%)
Duration of SAD (yrs) m: 12.9 sd: 7.3
Baseline LSAS score m: 62.4 sd: 10.6
Baseline HSRD score m: 12.68 sd: 2.42
Baseline CGI-S m: 4.8 sd: 1.1
CGI-I (Paroxetine trial) m: 4.3 sd: 0.5
Baseline SDS Work m: 7.6 sd: 1.8
Baseline SDS Social m: 8.5 sd: 2.0
Baseline SDS Family m: 5.2 sd: 1.3
Baseline ASEX m: 19.4 sd: 2.3
Lifetime comorbidity
Axis I Depressive disorder 5 (17.2%)
Cyclothimia 2 (6.9%)
Panic disorder 6 (20.7%)
Somatoform disorder 3 (10.3%)
Obsessive-Compulsive Dis. 2 (6.9%)
Alcohol abuse 5 (17.2%)
Substance abuse 2 (6.9%)
Axis 2 Avoidant PD 4 (13.8%)
Obsessive-Compulsive PD 1 (3.4%)
Passive-Aggressive PD 1 (3.4%)
Narcissistic PD 1 (3.4%)
Key:
LSAS: Liebowitz Scale for Social Anxiety.
HSRD: Hamilton Depression Rating Scale.
CGI-S: Clinical Global Inventory-Severity.
CGI-I: Clinical Global Inventory-Improvement.
SDS: Sheehan Disability Scale.
ASEX: Arizona Sexual Experience Scale.Clinical Practice and Epidemiology in Mental Health 2006, 2:35 http://www.cpementalhealth.com/content/2/1/35
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More specifically, in our study escitalopram appeared
more tolerable in terms of sexual side effects in compari-
son with paroxetine in the same subjects, as evidenced by
the reduction of several ASEX subscales from baseline
(under paroxetine treatment) and at the end of the trial
(under escitalopram treatment). Lader et al found that the
percentage of sexual side effects (ejaculation failure,
libido decreased, impotence) associated with escitalo-
pram 20 mg/day and paroxetine 20 mg/day in SAD were
roughly similar [20]. It is of note that all our group of
patients had previously failed an adequate trial of paroxe-
tine treatment at dosage >= 60 mg/d for >= 12 weeks. It is
also our clinical experience that a paroxetine dosage of 20
mg/day can be considered low for the treatment of SAD.
We believe that the relatively low sexual side effects found
by Lader et al using paroxetine was due to the sub-thera-
peutical dosage of this drug.
Conclusion
Escitalopram extends the possibility of treating subjects
with SAD who are resistant or intolerant to other SSRI or
IMAO treatment. Given the safe side effects profile, the
possibility of using it for non-resistant patients should
also be considered. At this time we believe that this sched-
ule may be useful in treating SAD non-responders.
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